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ABSTRACT 
Towards engineering approaches that are designed to optimize the particle size, morphology and 
mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents 
the preparation, physicochemical characterization and preliminary in vitro evaluation of 
multicomponent polymer-lipid systems that are based on “spray-drying engineered” α-lactose 
monohydrate microparticles. The formulations combine an active (budesonide) with a lung 
surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable 
effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion 
(chitosan). The effect of the composition of formulations on the morphology, distribution and in 
vitro mucoadhesion profiles is presented along with “Calu-3 cell monolayers” data that indicate 
good cytocompatibility and also with simulated-lung-fluid data that are consistent with the 
therapeutically useful release of budesonide. 
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INTRODUCTION 
Elevated blood flow and a large surface area (100 m2) render the human lung network a suitable 
site for the rapid absorption of therapeutic compounds.1 The pulmonary delivery of drugs by 
means of inhaled aerosols is regarded as a minimally invasive route of administration and offers 
the additional advantages that are associated with the avoidance of the hepatic first-pass effect. 
The benefits of the approach are counterbalanced by the challenges associated with the efficient 
delivery of therapeutic formulations to the lungs, which is often impeded by physiological 
barriers that inhibit the efficient deposition, residence time and drug release characteristics of 
formulations. For effective delivery of therapeutic compounds to the alveolar area of the lungs, it 
is desirable that solid components of inhalable formulations have a mean aerodynamic diameter 
in the range 1-5 µm.2 Associated with this are the good aerosolization properties of particles, 
such that aggregation is prevented.3 Also, to overcome the action of the mucociliary apparatus,4,5 
the particles must be mucoadhesive, such as to become instantaneously integrated into the 
mucosa layer of the lungs. To this end, many excipients (sugars,6,7 lipids,8,9 amino acids,10,11 
polymers12,13) have been evaluated14 but lactose has remained the material of choice for 
commercial formulations over many years.15  
The method of choice for the manufacturing of both local and systemic formulations for the 
delivery of therapeutic agents to the respiratory system is spray drying.3,16,17 Within the context 
of particle engineering, spray drying is an established method for the formulation of drug-loaded 
particles since it is compatible a wide range of materials18 and offers the capability to fine-tune 
multicomponent formulations through the incorporation of an array of well-studied excipients in 
a one-step method that allows the ready incorporation of therapeutic compounds.19–22 
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This paper describes the engineering, by spray drying, of multicomponent formulations for the 
pulmonary delivery of the corticosteroid budesonide (BD), which is widely used for the 
treatment of asthma. In accord with established technologies, the bulk material of the 
formulation is α-lactose monohydrate (LCS). The other components of the formulation include:  
polyvinyl alcohol (PVA), which is reported to enhance the morphological characteristics of 
particles and to improve their drug-release properties;23–25 dipalmitoylphosphatidylcholine 
(DPPC) lung surfactant;26–29 L-leucine (L-LC) aerolization modifier;25,30,31 and chitosan (CS) 
bioadhesive.32–35 To facilitate the selection of optimal compositions, these formulations are 
assessed for their production yield, morphological characteristics, and surface charge. Thermal 
analysis and infrared spectroscopy are used to further characterize promising formulations, and 
these studies are complemented by laser diffraction investigations of particle size distribution 
and aerolization performance, and also by in vitro deposition studies. The in vitro release of the 
incorporated active is assessed in simulated lung fluid. To simulate the in vivo challenges that are 
presented to the formulations by the mucosal barrier at the surfaces of the lung, assessment tools 
are deployed for the evaluation of the mucoadhesive properties of the microparticles under 
investigation.  Both the adhesion profiles of microparticles in contact with mucus and the effects 
of this interaction on the cohesiveness of the resultant gel are considered for the purpose of 
identifying a potentially therapeutically useful formulation. Finally, cell proliferation and 
epithelial integrity studies are used to evaluate the effect of formulations on the Calu-3 cell line.  
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EXPERIMENTAL SECTION 
Materials. Budesonide (≥99%), polyvinyl alcohol (Mowiol 4-88, MW~31000), L-leucine 
(≥98%), low molecular weight chitosan (MW 50000-190000), Rhodamine B (≥95%), 
diethylenetriaminepentaacetic acid (≥99%), RPMI 1640 amino acids solution, deoxyribonucleic 
acid sodium salt from salmon testes, mucin from porcine stomach type II and gelatin from 
bovine skin type B were all purchased from Sigma-Aldrich, Germany. α-Lactose monohydrate 
was purchased from DMV International, Netherlands. Egg Yolk Emulsion for Microbiology was 
sourced from Merck, Germany. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was 
obtained from Avanti Polar Lipids. All other materials and reagents were of analytical grade. 
Homogenised Mucus. An aqueous mixture was prepared from sodium chloride (0.9% w/v), the 
bacteriostatic agent sodium azide (0.02% w/v), the oxidation-inhibiting chelating agent 
ethylenediaminetetraacetic acid (0.186% w/v) and an ethanolic solution (1ml) of the protease 
(cell-degradation) inhibitor phenylmethylsulphonyl fluoride (0.0175% w/v). The mixture was 
made up to 100ml with distilled water and brought into the solution phase by stirring (12 hours, 
room temperature). In accord with the procedures dictated by the Science Faculty Ethics 
Committee of the University of Portsmouth, crude sputum (100 ml) was collected from two 
unfed (3 hours) healthy human volunteers (one male, one female; both 24 years of age) over a 
period of approximately 3 hours (The average daily flow of whole saliva in healthy subjects 
varies between 1 and 1.5 L36) and subjected to vacuum (Buchner) filtration (twice) to remove 
any buccal cells, food debris and other large particles. The thus treated mucus was preserved by 
freezing at -18ºC. 
Preparation of engineered microparticles. Three sets of multicomponent carriers (MCs) were 
produced by the spray drying technique, namely: budesonide-free (empty), budesonide-loaded 
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and Rhodamine B-loaded microparticles. For each set, the effect of variations in the proportions 
of excipients was assessed at two specified ratios of the utilized liquid media (water and ethanol). 
The compositions of empty formulations are listed at Table 1. The excipients PVA, LCS, DPPC, 
CS and L-LC were incorporated into the formulation from feed solutions. To prepare each 
formulation, the lipid DPPC was dissolved in a specified volume (70 or 85 mL) of ethanol. In 
parallel, PVA was dissolved in a predetermined amount of hot (90 ºC) water (either 25 or 10mL), 
and once PVA had dissolved, LCS and L-LC were added in sequence to each solution. 
Separately, CS was dissolved in water containing 1% acetic acid (5 mL). The two aqueous 
solutions were mixed to form the aqueous phase, which in turn was added very slowly to the 
organic phase – such as to avoid the precipitation of the lipid compound or the formation of 
liposomal structures. The mixing of the alcoholic and aqueous solution was in such ratios as to 
afford formulations that had a total volume of 100 mL and a solid content of 0.1% w/v.  
To prepare loaded formulations, selected compositions of empty feed solutions were prepared 
from budesonide (BD) and budesonide plus Rhodamine B (RH) feed solutions at 5% w/w (5 mg 
BD or BD+RH per 100 mg of total solids). In both cases, BD and RH were respectively added to 
the ethanolic and aqueous solutions while the lactose content was reduced by an equal (weight) 
amount, such as to maintain the total solid content of the final feed solution at 0.1% w/v. To limit 
the effect of evaporation on the total volume of the liquid media, the feed solutions were 
subjected to gentle stirring (5 min) at 50 ºC; the boiling points of H2O:EtOH at 30:70 v/v is at 85 
ºC while that at 15:85 v/v is 80 ºC.37 The feed solutions were spray dried using a Buchi Mini 
Spray Dryer B-191 (Buchi, Switzerland) operating at: inlet temperature, 100 ºC; airflow, 600 
L/h; respective aspirator and pump rates of 100 % and 4.5 mL/min; and, outlet temperature of 
60-65 ºC. To calculate the yield of the spray-drying process, each batch of MCs was weighed and 
Page 6 of 44
ACS Paragon Plus Environment
Langmuir
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 7
the percentage yield was determined from: Yield%=mf/mi×100; where mi is the initial mass of 
solids in feed solutions and mf is the collected mass of MCs. To quantify drug loading, an 
accurately weighed amount of ca. 2 mg of each sample was added to EtOH (5 mL). This mixture 
was stirred continuously for 24 h before the solid content was separated by centrifugation (4000 
rcf, 15 min). The drug content in the supernatant was determined by HPLC and percentage 
loading was calculated from: DrugLoad%=mBD/mBD-MC×100, where mBD is the determined mass 
of budesonide and mBD-MC is the mass of drug loaded MCs dispersed in EtOH. In a similar 
manner, the drug loading of RH in the carriers was quantified spectrofluorimetrically following 
dissolution of the dye-containing carrier (3 mg) in EtOH (10 mL). Microparticles were stored in 
a CaCl2 desiccator.  
Scanning electron microscopy and ζ-potential studies. To assess particle morphology, both 
empty and loaded microparticles were visualized using a Zeiss SUPRA 35VP SEM microscope. 
Dispersion stability studies were performed by means of a Zetasizer Nanoseries Nano-ZS 
analyzer (Malvern, UK). Microparticles were dispersed in distilled water (0.2 mg/mL), sonicated 
(15 s), and ζ-potential determinations were performed in triplicate. 
Infrared spectroscopy and thermal analysis. The infrared spectra (650-4000 cm-1, 2 cm-1 
resolution) of loaded formulations and of each of their constituents were obtained using an IR 
Prestige-21 (Shimadzu, Japan) instrument. Differential Thermal analyses (5mg, aluminum pans, 
20-350 ºC, 10 ºC /min) of selected empty, loaded and pristine materials were performed using a 
DSC 204 F1 Phoenix (Netzsch) instrument.  
Laser diffraction analysis. Laser diffraction (Malvern Spraytec; Malvern, UK) studies allowed 
the evaluation of the particle size distribution (PSD) of loaded carriers: Gelatin capsules were 
filled with approximately 15 mg of the formulation under study, and these powders were 
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delivered by attaching a breath-activated spray delivery device to a USP throat that had been 
mounted onto the Spraytec device. A 300 mm focal length lens (specified for the particle size 
range 0.1-900 µm) was used and the respective refractive indices for particles and dispersant (air) 
were set at 1.330 ± 0.001 and 1.000 ± 0.001. Light scattering patterns were recorded in triplicate 
at the flow rate of 30 L/min and the volumetric percentiles Dv(10), Dv(50), Dv(90): the 
percentage of particles with geometric diameter < 5µm and the span of the distribution was 
recorded. 
In vitro aerosolization and deposition. The aerodynamic performance of Rhodamine-loaded 
microparticle formulations was evaluated by the PSD analysis of data obtained using an 
Andersen Cascade Impactor (ACI) in a configuration that had been designed to simulate the 
deposition of particles on the respiratory tract. To this end, an accurately weighed amount (ca. 60 
mg) of Rhodamine-loaded MCs was divided equally amongst three gelatin capsules. The device 
was allowed to equilibrate to steady flow (30 L/min for 10 min), after which time the 
Rhodamine-loaded MCs were introduced in the ACI over 15 sec at the same air flow rate. The 
air flow was then interrupted, and the device was allowed to equilibrate for an additional period 
of 2 min. The ACI stages were disassembled, rinsed (ethanol) and the deposited MCs at each 
stage were collected in separate glass vials. To facilitate the solubilization of RH, each of these 
ethanolic solutions was kept under stirring for 2 h (room temperature). To separate the insoluble 
mass, aliquots of each solution were centrifuged at 4000 rcf for 20 min, and the amount of RH 
deposited in each stage was quantified by spectrofluorimetry measurements (RF-5301-PC 
Fluorescence Spectrophotometer, Shimadzu): excitation (570 nm) and emission (590 nm) at 
respective slit widths of 3 and 5 nm. The calibration curve of Rhodamine was linear over the 
range of 0.01-0.05 µg/mL (R2 ≥ 0.999). Data for the % cumulative RH mass that had been 
Page 8 of 44
ACS Paragon Plus Environment
Langmuir
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 9
adjusted for the stated aerodynamic diameter were plotted, on a semi-log, as a function of the 
respective aerodynamic diameter, according to Ph.Eur. The fine particle fraction (FPF) was 
derived at 5 µm cut-off diameter and the mass-median aerodynamic diameter (MMAD) was 
determined at 50% cumulative mass. The geometric standard deviation (GSD) was calculated 
from GSD=(AD84.13/AD15.87)
1/2, where AD84.13 and AD15.87 are the aerodynamic diameters 
representing cumulative masses of 84.13% and 15.87%, respectively. 
The behavior of microparticles in artificial mucus. The behavior of empty and RH- loaded 
MCs was investigated by ζ-potential measurements and by permeation studies, respectively in 
mucin dispersion and in artificial mucus.38 ζ-Potentials of empty formulations were recorded in 
mixtures with mucin dispersion (0.02% w/v).  
In an effort to assess the capability of RH-loaded microparticles to penetrate the mucus layer of 
the respiratory system, preliminary permeation studies were conducted by means of an 
established in vitro model. 38 (The adopted model is not capable of simulating the in vivo 
conditions; it is a tool for the pre-screening of the capability of carriers to participate in 
mucoadhesive interactions.) This barrier was simulated by a layer of gelatin that had been placed 
at the bottom of a test tube and covered with artificial mucus consisting of an aqueous dispersion 
of DNA, mucin, sterile egg yolk emulsion, diethylenetriaminepentacetic acid, sodium chloride, 
potassium chloride and RPMI medium. A specified volume of an aqueous dispersion of 
microparticles was placed on the artificial mucus layer. The test tubes were kept at room 
temperature for 24 h, after which time the amount of Rhodamine that had penetrated the mucus 
and became deposited on the gelatin layer was quantified by fluorimetry. Experiments were 
conducted in triplicate.  
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To further assess the mucoadhesive properties of the BD loaded formulations, a Stable Micro 
System (TA.XT.plus) Texture Analyser was employed to record their combined adhesion-
cohesion profiles following integration into homogenized mucus. Onto the probe was attached, 
by means of double-sided adhesive tape, an accurately weighted amount (ca. 5 mg) of the sample 
under test, while onto the holder stage of the device was deposited homogenised mucus (ca. 0.25 
mL). The probe moved downward to establish contact with the mucus layer before being 
withdrawn at a specified constant rate. The experiments were performed under a force of 5 g, a 
contact time of 10 s and probe speed of 1 mm/sec. The mucoadhesion profiles were recorded as 
plots of force versus time.  
In vitro release in Simulated Lung Fluid. Release studies were carried out in simulated lung 
fluid (SLF).39,40  Each BD loaded sample (8 mg) was separately suspended in SLF (4 mL) that 
had been maintained at 37 ºC. Dialysis bags (12,000 - 14,000 molecular weight cut-off) were 
filled with each suspension (1 mL) and immediately immersed in an SLF-containing (20 mL) 
glass vial maintained at 37 ºC. Drug release was carried out over 24 h in a shaking thermostatic 
(37 ºC) water bath. At predetermined time intervals (0, 5, 10, 20, 30, 60, 90, 120, 180, 240, 300, 
360, 720 and 1440 min), aliquots of 1 mL of the release medium were withdrawn, and instantly 
replaced with fresh SLF. The concentration of BD in each aliquot was determined using an 
HPLC system consisting of an LC-10 AD VP pump, a SIL-20A HT autosampler and a UV-Vis 
SPD-10A VP detector that had been interfaced to Class VP Chromatography data system v.4.3 
(Shimadzu):41 stationary phase, Ascentis C8 column (150 mm, 4.6 mm, 5µm); mobile phase, 
acetonitrile potassium dihydrogen phosphate (60:40 v/v; 0.025M; pH 3.2, adjusted with 
phosphoric acid). The mobile phase was degassed (sonication, 20 min) before each 
measurement. The flow rate and injection volume were 1.1 mL/min and 10 µL, respectively. The 
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detection of BD (retention time, 4.6 min) was at 244 nm. The sample run time was 6 min. The 
calibration curve of budesonide was seen to be linear over the of range 0.1-0.6 µg/mL (R2 ≥ 
0.999). 
Calu-3 cell studies. The Calu-3, human adenocarcinoma-derived cell line, was used throughout 
the course of this study, from passages 25-33 in the transport experiments. Calu-3 cell cultures 
were grown in 75 cm2 flasks (Corning Costar Corp., USA) in DMEM/F12 (Invitrogen Gibco, 
USA) medium that had been supplemented with 10% v/v Fetal bovine serum (FBS) and 100 
µg/mL of penicillin/streptomycin and allowed to grow to 70-80% confluency. These were 
transferred in Transwell inserts (0.4 µm pore size, Corning Costar Corp., USA) at a density of 5 
x 105 cells per well, and the cells were permitted to proliferate (37 ºC) in a humidified 
atmosphere containing 5% v/v CO2. The cells were allowed to grow (Transwell inserts, 48 h) 
under liquid culture conditions (LCC), after which time the medium of the apical side was 
removed – thus allowing these cells to grow at the air interface environment (AIC). Every 48 h, 
the culture medium on the basolateral side was replaced and the integrity of the Calu-3 
monolayer was ascertained by monitoring the transepithelial electrical resistance (TEER). 
Measurements were carried out using a Millicell ERS Voltohmmeter (EMD Millipore) equipped 
with chopstick electrodes. The daily monitoring of TEER values of monolayers allowed the 
selection of those giving readings >180 Ω*cm2. The measured TEER values were expressed as 
the percentage of those for control (untreated) cultures. To assess cell monolayer integrity and 
permeability, the TEER of Calu-3 monolayers that had been incubated with test formulations (1 
mg/mL) was monitored at 60 min intervals over 240 min (Millicell-ERS; Millipore, Bedford, 
MA). The capability of the such treated monolayers to recover from the effects of the treatment 
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was assessed by washing the cell cultures with DMEM (to remove the formulations), before 
fresh HBSS/HEPES buffer was added and the TEER being monitored for a further 240 min. 
Cytotoxicity assays. The cellular proliferation capacity of Calu-3 cells was assessed by exposing 
cultures to specified concentrations of the microparticles under test. Calu-3 cells were seeded at a 
density of 105 cells per well in 24-well culture plates (Corning Costar Corp., USA) and allowed 
to grow for a period of 48 h. Cells were then washed with PBS (pH 7.4) and the medium was 
replaced with 1 mL of FBS-free medium containing varying concentrations of the agents under 
investigation. The cell growth was measured by counting the number of cells in culture, using a 
hemocytometer. The viability of Calu-3 cells was assessed using the Trypan Blue method.42  
Statistical analysis. All measurements are presented as mean ± SD. Values of P<0.05 are 
considered to denote statistical significance (Student’s t-test). 
 
RESULTS AND DISCUSSION 
Evaluation of engineered microparticles. The solid composition of empty feed solutions, the 
calculated process yields and the ζ-potential values of empty MCs are presented at Table 1. 
Irrespective of variations in the proportion of excipients, in most cases, the spray drying process 
was associated with yields in the range 28 - 32%. Indicative of the role of PVA as the core 
material of formulations, S1 was produced at a low yield. In light of literature reports,43 it is 
assumed that the yield of the process.is markedly influenced by the proportion of DPPC in the S1 
formulation (S1 has the highest content of DPPC among all formulations under consideration).  
In the processing of samples with the same composition (S3-S7 and S5-S6), the proportion of 
EtOH in the H2O:EtOH medium (30:70 or 15:85) had a negligible effect (P>0.05) on the yield of 
the process if all other process parameters remained unaltered; indicating that the lower boiling 
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point of the more ethanolic medium does not accelerate the drying process, presumably due to 
molecular-level solvent association phenomena.  
The surface charge studies reflected the strong dispersion stability of the empty particles in H2O, 
with positive ζ-potential values in the range of 28.7-51.4 mV originating from the positive 
charge of CS44 and also from the zwitterionic nature of the DPPC molecule which favours 
positive charges in the moderately acidic aqueous environment.45 The influence of DPPC content 
on the ζ-potential was investigated in formulations having a fixed proportion of chitosan. Marked 
differences were noted between samples of low and high DPPC content. Indicative of plateau 
effects, however, S1 (40% DPPC) was characterized by a very similar ζ-potential to S5 (30% 
DPPC):  respectively 29.3 ± 1.7 mV and 28.7 ± 1.5 mV. The corresponding differences between 
S2 (20% DPPC) and S3 (15% DPPC) were somewhat more pronounced at 40.8 ± 0.9 mV and 
37.5 ± 0.6 mV, respectively. It is possible that the indicated increases in surface charge with 
increasing proportions of the nonionic core excipients, PVA and LCS, reflect the migration of 
the positively charged CS and DPPC molecules to the outer layer of particles. Amongst the 
empty MCs, the highest ζ-potential (51.4 mV) was associated with S4, which was formulated 
with triple the amount of CS (6% vs. 2%).  
The size and morphological features of empty MCs were assessed by SEM imaging. Large 
particles (>>5 µm) were observed with S1 and S2 (Supplementary information, Figure S1). The 
SEM observations showed that other desiccated particles were approximately spherical and had 
smooth surfaces, and that their sizes were in the therapeutically useful range of 0.5-5.0 µm, 
Figure 1 (A, B, and C). The combined evaluations of experimental findings from the spray 
drying process, ζ-potential measurements and SEM imaging, allowed the selection of three 
candidate formulations for loading with BD and RH, namely: S3, S4 and S6. 
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Loaded formulations were prepared in an identical fashion to their free congeners by substituting 
5% w/w of BD or RH for an equal proportion of LCS, such as to maintain a constant total 
content of solids at 0.1% w/v, Table 2. The incorporation in the formulation of the drug or the 
fluorescent molecule did not affect significantly the yields of formulations as compared with 
those associated with their empty counterparts (p>0.05): 29.2-33.8% and 31.1-34.6% 
respectively for budesonide and Rhodamine-loaded microparticles. Similarly, SEM micrographs 
revealed that budesonide did not effect any significant changes to morphology, Figure 1 (D, E, 
and F).  
FTIR and DSC analysis. The FTIR spectra of pure BD, of each excipient and of drug loaded 
samples are presented in Figure 2. Pure budesonide exhibits characteristic bands at 3491 cm-1 
(OH stretch), 2947 cm-1 (CH2 stretch), 1718 cm
-1 and 1664 cm-1 (C=O stretches) and 1624 cm-1 
(C=C).46,47 None of these features were indisputably visible in the spectra of loaded formulations 
(owing to the masking effect of the DPPC component, which is characterized by a broad OH 
stretch (3150cm-1 - 3550cm-1) and absorptions at 2916 cm-1, 2848 cm-1 and 1732 cm-1, 
respectively due to CH2 asymmetrical and symmetrical stretches and the C=O stretching 
vibration48). The dominance of DPPC is demonstrated by the intensity of BD1 bands (30% w/w 
DPPC) as compared with those of BD2 or BD3 (15% w/w DPPC).  
DSC traces of constituents and formulations are presented in Figure 3. The thermogram of DPPC 
exhibits a broad endotherm in the range of 38-54 ºC, which is assumed to mark the transition 
from gel to a lipid-crystalline state. The melting endotherm of PVA was observed at 193 ºC, 
while evidence for the oxidative degradation of this polymer is provided by a peak that is 
centered at ca. 325 ºC. CS presented a dehydration endotherm that was centered at ca. 104 ºC, 
and an exothermic decomposition that is onset at ca. 280 ºC. The thermograms of LCS, pure BD 
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and L-LC indicated the melting temperatures of these components at 240 ºC, 260 ºC and 320 ºC, 
respectively. The thermograms of BD formulations were marked by endothermic phenomena 
over the temperature range 230-320 ºC. As compared with the DSC traces characterizing the 
base component of the macroparticulate formulation, there is observed a shift in the positions of 
the observed transitions of formulations towards higher or lower temperatures that is notably 
dependent upon the relative ratios of LCS, BD and L-LC. Since spay-dried LCS is well known to 
exist in the amorphous state but to become progressively crystalline over time,49 it is assumed 
that it is the influence of the proportion of the other components of the formulation that 
determines the rate of the crystallisation process and hence the thermal behavior of the 
formulation. BD3, which has the maximum content of LCS and minimum content of L-LC, 
exhibits a melting endothermic which is centered at 276 ºC while for BD2 the same transition is 
at 278 ºC. Indicative of phase separation, BD1 exhibits a two-stage melting process with a 
distinct inflexion at 270 oC and a shoulder at 287 oC. Accordingly, it is assumed that BD1 
behaves as a multicomponent system of its constituent molecules and that L-LC, BD and LCS 
are key to the intimate mixing of the constituent molecules at the molecular level; as is the case 
with BD2 and BD3. Comparative studies involving the empty formulations show heat capacity 
minima at 277 ºC and 275 ºC respectively for S4 and S3, which are consistent with those 
observed with the corresponding loaded formulations BD2 and BD3. S6 exhibits distinct minima 
at 269 ºC and at 287 ºC, which show that the replacement of the BD content by an equal amount 
of LCS effects a slight shift (1 ºC) in the minima towards lower temperatures. The higher-
temperature melting endotherms of BD formulations as compared with those of their S 
counterparts is consistent with successful loading.   
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Particle size distribution and in vitro deposition. Particle sizes of loaded formulations, as 
determined by laser diffraction, are presented in Table 3. The volumetric median diameter of the 
samples, which is related to the geometric diameter, was in the range 8.98-9.74 µm (P<0.05), 
while the percentage of particles with size <5µm was about 20% for BD1 and 23% for BD3; 
representative size distribution plots are presented in Figure 4A-C. In accord with SEM data, 
BD3, which has the highest content of PVA and LCS, is confirmed as the formulation that 
exhibits the most useful, for the proposed use, size distribution profile. By contrast, the size 
distribution profile of BD1, which has the lowest PVA and LCS contents, was sensitive to 
increases in the volumetric percentiles and to the volumetric fine particle fraction. Data for BD2 
(volumetric median diameter, 9.29 µm; 21.96% particles <5 µm) confirm the aerosolization 
effect of L-LC31,50 (c.f. BD1). Large particles were formed in BD formulations, and these are 
reflected in incremented Dv(90) values of 26.43 µm, 26.84 µm and 30.33 µm, respectively for 
BD2, BD3 and BD1. The size plots of the drug loaded formulations revealed unimodal 
distributions with spans in the range 2.30-2.75 µm. 
The particle size analysis was complemented by in vitro deposition studies of Rhodamine-loaded 
formulations using the multistage-ACI. The Rhodamine formulations were prepared under 
identical condition to those used for the drug-loaded samples, such that they provide a 
fluorescently labelled congener of the therapeutically useful formulation, which can be used to 
compare size distribution data from laser diffraction experiments and the ACI-mediated 
aerosolization studies.  
The deposition of the RH-loaded MCs onto the stages of the ACI is illustrated at Figure S2 
(Supplementary Information). The deposited particles were seen to form as spots that were 
distributed over the surface of each level. This is attributed to capillary air flow at the lower 
Page 16 of 44
ACS Paragon Plus Environment
Langmuir
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 17
stages of the ACI device. The particle size distributions and the calculated MMAD, GSD and 
FPF values of Rhodamine microparticles are presented in Figure 4D and summarized in Table 3. 
Consistent with expectation on the basis of PVA-LCS content, ca. 65% of particles RH3 
presented an aerodynamic diameter <5 µm and a mean diameter of ca. 4 µm. In accord with 
expectation, the low PVA and LCS-content formulations RH1 and RH2 were characterized by 
aerodynamic diameters of ca. 6 µm and respective FPFs of 23% and 38%. Since the PVA and 
LCS content of RH1 and RH2 is almost identical, the marked differences in behavior observed 
for these two formulations must be linked to the threefold difference in content of the 
aerolization excipient L-LC. The presence of large particles was reflected in the ACI size 
distribution profile of RH-loaded microparticles. The technique-dependent variability in 
observed mean particle size is well documented: laser diffraction measurements give appreciably 
longer mean diameters than impaction studies due to the effects on aerosolization performance of 
slip, shape and density.51,52 The density of microparticles studied by impaction appears to have 
been affected by the incorporation of RH. This is reflected by the lower MMAD values relative 
to the corresponding geometric diameters determined for BD formulations. It is possible that 
aerolization performance also reflects changes in the shape of microparticles, which in turn are 
consequent to the differences in composition. Marked differences between MMAD values and 
geometric diameters were observed with all three formulations. 
The behavior of microparticles in artificial mucus. Dispersion in the mucin medium effected a 
reduction in the surface charge of empty formulations. The influence of the mucoadhesive 
content CS to the ζ-potential of the system is illustrated in Figure 5A. Indicative of the strong 
association of particles with mucin, the surface charge of S3 was seen to be reduced from 37.5 
mV to 8.8 mV while those for S6 and S4 were correspondingly reduced to 9.8 mV and at 10.2 
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mV. For comparison, the mucin medium is characterized by a surface charge of -18.6±1.45 mV. 
Consistent with the strong association of mucin with MCs is the observed unimodal distribution 
profiles characterizing the ζ-potential measurements (Supplementary Information Figure S3). 
In accord with their limited impact on the integrity of the mucus layer, the fluorescently modified 
formulations penetrated the artificial mucus layer to a limited extent, Figure 5B, with RH1 and 
RH3 presenting values of 3.25% and 2.21% penetration, respectively; these differences are 
statistically significant at the p<0.05 level. Notably, of these two formulations, it is RH1 (the 
formulation with the higher DPPC content; DPPC is a natural component of mucus) that displays 
a higher propensity for the mucin network. The influence of CS is exemplified by the behavior of 
RH2, which was characterized by a corresponding value of 5.34% (p<0.05).  
Penetration through mucus was followed visually over a 24 h period (Figure 5C). Large amounts 
of RH1 and RH2 were seen to penetrate the artificial mucus layer and deposit onto the gelatin 
surface. For the RH3 formulation, the number of particles approaching the gelatin surface was 
seen to be limited by the observed rate of penetration through mucus.  
The behavior of BD microparticles in homogenised mucus. The mucoadhesion performance 
of budesonide-loaded MCs was studied further with the aid of a texture analyzer. In an 
experiment designed to assess the mucoadhesive behavior of BD formulations, a physiologically 
relevant amount of each of BD1, BD2 and BD3 was mixed with a specified amount of 
homogenized mucus. A specified amount of each mixture (0.25 mL) was placed onto a glass 
slide with the aid of an automatic pipette.  Each glass slide was placed on the TA stand. The TA 
probe was set to exert a force of 5g and lowered into the probed sample. After 10 seconds the 
probe was raised and the detachment profile was recorded. For control experiments, 
homogenised mucus was replaced by distilled water. A comparative assessment of the profiles 
Page 18 of 44
ACS Paragon Plus Environment
Langmuir
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19
characterizing each of the BD formulations showed that all formulations were similarly 
mucoadhesive and also identified BD2 as that associated with slightly stronger mucoadhesive 
interactions (as quantified by the area under the mucoadhesion curve; work of adhesion) and also 
the desirable property of instantaneous (<<2 sec) onset of mucoadhesive behavior 
(Supplementary Information, Figure S4). 
To assess the effect of contact time between the BD solids and mucus, a sample of each type of 
microparticle was placed onto one side of double-sided adhesive tape, the other side of which 
was attached to the flat end of the probe (Supplementary Information, Figure S5), and the probe 
(set at a force of 5g) was again lowered into the homogenised mucus (0.25mL) and allowed to 
interact for a specified time (10 sec) such that the microparticles become integrated into the test 
medium) before the raising of the probe; microparticles-free homogenised mucus provided the 
control. Data for the 10 sec experiment, presented as Supplementary Information (Figure S6), 
confirm the rapid integration of BD2 into the mucus layer. In accord with expectation on the 
basis of differences in surface energy, comparative data collected for the BD formulations in 
contact with homogenized mucus or with a distilled water control indicated the higher affinity of 
the formulations for mucus than for water, as is illustrated by the longer acting force of adhesion 
for BD2 against homogenized mucus as compared with that against distilled water. Comparison 
(Figure 6) of the shapes of the positive portions of the force vs time curve reveals the maximum 
forces exerted onto the probe by the water or mucus media are very similar (as demonstrated by 
the comparison of peak maxima) but, consistent with more cohesive nature of the mucus-
microparticle system, the detachment of the probe from the mucus substrate occurs over a longer 
time period. Nonetheless, the data is semiquantitative (the results are presented as force vs time 
plots, since conversion into Work of Adhesion data is impeded by the ill-defined limits of the 
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integration) due to the small but significant variations in the number of particles initially held by 
the double-sided adhesive tape. The negative part of the same plot (Figure 6) is characterised by 
two distinct segments. Instantaneous adhesive interactions develop between the probe and either 
medium, but between time 0 and the onset of the 10 sec plateau (interaction time) there is a 
marked difference in behaviour: the pulling force (adhesion) exerted by water on initial contact 
with the microparticle-decorated probe is more pronounced than that exerted by mucus but after 
the 10 sec interaction time, the adhesive-interaction profiles become identical.  
Since all BD formulations developed mucoadhesive interactions well within the 10 sec 
timescale, to provide an indication of the time-dependence of the mucoadhesive effect 
characterising each formulation, mixtures (0.5 ml) of each of the BD formulations and 
homogenised mucus were placed in separate vials of identical dimensions. (Parallel control 
samples utilised distilled water in the place of homogenised mucus.) The mucoadhesion profiles 
(force, 5g; probe contact time 10 sec) recorded at 5 min and at 30 min after mixing were 
identical, indicating that the mucus-mucoadhesive system was stable over this, therapeutically 
relevant, timescale.  
In vitro release studies in SLF. For all BD loaded MCs, the percentage loading of the drug was 
of the order of 4.9% w/w of the total mass of the formulation, which is in good agreement with 
the 5% w/w BD content in total solids incorporated in the feed solutions.  
Drug release in SLF was monitored over 24 h, Figure 7. Similar release profiles were recorded 
for all formulations over the first 60 min, with approximately 40% of the incorporated drug seen 
to be released. Observations over 12 h revealed distinct differences in release profiles. Under the 
adopted experimental protocol, BD3 released ca. 90% of its therapeutic content within 4 h; and 
almost 100% within 6 h. Corresponding release rates for BD1 and BD2 were of the order of 80% 
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at 4 h and 90% at 6h. These statistically significant (P<0.05) differences are attributed to the 
relatively high content of the water soluble molecules PVA and LCS in the BD3 formulation, as 
compared with the BD1 and BD2 homologues. Symptomatic of the influence exerted by its high 
proportions of lipid content and low proportions of water soluble components, BD1 released its 
entire drug content at a rate that decelerated progressively over the 24 h monitoring time period 
of the experiment.  
Cell viability studies. The data presented in Figure 8 (A, B & C) indicate that, over the 48 h 
timespan and at the <2 mg/mL concentration level, budesonide-loaded microparticles do not 
exert any noticeable adverse effect on the cellular proliferation of Calu-3 cultures. In parallel, no 
permanent effect on the integrity of the Calu-3 cells membrane was observed upon treatment 
with the microparticles under the same experimental conditions (Figure 8D).  
 
CONCLUSIONS 
A multicomponent microparticulate drug carrier has been developed, which is proposed to merit 
further investigation as vehicle for the efficient delivery of the corticosteroid budesonide to the 
respiratory tract. The microparticles were prepared at ca. 30% yield by means of a spray-drying 
process and formulations were engineered such that they exhibit good sphericity (mean particle 
size: 3.9-6.5 µm) and a surface charge in the range 29-51 mV.  To meet the performance 
demands that are integral to effective pulmonary delivery, the formulations incorporate a lung 
surfactant (dipalmitoylphosphatidylcholine, 15-45% w/w) with materials that are known for their 
desirable effects on morphology (polyvinyl-alcohol, 15-40% w/w), aerosolization (L-leucine 3-
9% w/w) and mucoadhesion (chitosan 2-6% w/w), and are further designed in a manner that 
allows the controlled release of a therapeutically active molecule (budesonide, 5% w/w). 
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Aerolization studies of the proposed microparticles indicated the promise of formulation 
BD3/RH3 (respective MMAD and FPF% values of 3.97µm and 65.16) as a means for the 
delivery of active compound to the lower respiratory tract. The suitability of the formulations for 
use in pulmonary therapy has been further indicated by evaluations employing two in vitro 
models of artificial mucosa to assess the effects of the mucus substrate on surface charge and to 
evaluate mucooadhesion and the mucosa-penetration profile. Mucoadhesion and mucus 
penetrating tests, identified formulation BD2/RH2 (MMAD, 5.64 µm; FPF, 38.28%) as that 
which merits further evaluation. The biocompatibility of the formulations has been indicated by 
studies that assessed the proliferation and integrity of Calu-3 cell monolayers. 
 
Supporting Information 
Figure S1. SEM micrograph of the typical morphology of distorted particles.  
Figure S2. Deposition of RH-loaded MCs at the stages of ACI. 
Figure S3. Typical ζ-potential measurement, showing unimodal distribution. 
Figure S4. Comparative mucoadhesion profiles for BD1, BD2 and BD3 in mixute with mucus. 
Figure S5. Schematic of the texture analyser probe showing the position of the test sample on the 
double-sided adhesive tape. 
Figure S6. The mucoadhesion profiles of BD1, BD2 and BD3 as obtained by the adhesive-tape 
test. 
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TABLES 
Table 1. Composition, process yield and ζ-potential values of empty formulations. 
 Excipient content %w/w Solvent Process Yield ζ-potential 
ID PVA CS L-LC DPPC LCS H2O:EtOH % mV 
S1 15 2 3 45 35 
30:70 
20.7 ± 2.7 29.3 ± 1.7 
S2 30 2 3 20 45 28.1 ± 1.4 40.8 ± 0.9 
S3 40 2 3 15 40 30.3 ± 0.9 37.5 ± 1.6 
S4 35 6 9 15 35 29.7 ± 0.8 51.4 ± 0.3 
S5 30 2 3 30 35 28.9 ± 1.8 29.7 ± 1.5 
S6 30 2 3 30 35 15:85 32.1 ± 1.5 32.3 ± 2.4 
S7 40 2 3 15 40  31.3 ± 1.2 33.8 ± 1.3 
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Table 2. Composition and process yield of budesonide- or Rhodamine B-loaded formulations. 
 Excipient content %w/w Process Yield 
ID PVA CS L-LC DPPC LCS BD RH % 
BD1 30 2 3 30 30 5 - 33.8 ± 1.1 
BD2 35 6 9 15 30 5 - 30.4 ± 1.8 
BD3 40 2 3 15 35 5 - 29.2 ± 1.6 
RH1 30 2 3 30 30 3 2 34.6 ± 1.9 
RH2 35 6 9 15 30 3 2 31.1 ± 1.3 
RH3 40 2 3 15 35 3 2 31.9 ± 1.5 
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Table 3. Size distribution parameters of budesonide and Rhodamine B-loaded formulations. 
 Spraytec Particle Analysis Andersen Cascade Impactor 
Formulation Dv(50) µm Span particles<5µm % MMAD µm GSD FPF% 
BD1/RH1 9.74 ± 0.29 2.75 ± 0.10 20.46 ± 0.55 6.51 ± 0.15 1.32 ± 0.17 22.67 ± 1.28 
BD2/RH2 9.29 ± 0.18 2.48 ± 0.08 21.96 ± 0.44 5.64 ±0.21 1.2 ± 0.19 38.28 ± 2.01 
BD3/RH3 8.98 ± 0.22 2.30 ± 0.07 23.57 ± 0.47 3.97 ± 0.24 2.5 ± 0.21 65.16 ± 2.34 
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FIGURE LEGENDS 
FIGURE 1: SEM micrographs of empty (A, B, C) and drug loaded (D, E, F) formulations. 
A:S3, B:S4, C:S6, D:BD1, E:BD2, F:BD3. 
 
FIGURE 2: FTIR spectra of loaded formulations and of their components. 
 
FIGURE 3: DSC thermograms of (A) pure components and (B) empty and drug loaded 
formulations. 
 
FIGURE 4: Size distribution of (A) BD1, (B) BD2, and (C) BD3 formulations, as obtained by 
Spraytec analysis software; and, (D) deposition of RH-loaded particles at the stages of the 
Andersen cascade impactor. 
 
FIGURE 5: (A) The effect of mucin medium on the ζ-potentials of the carriers. (B) Permeation 
studies of Rhodamine B-loaded formulations on artificial mucus. (C) Illustration of the 
penetration procedure through artificial mucus, observed visually after 24 h of exposure.  
 
FIGURE 6: The interaction of BD2 with homogenized mucus and with the distilled water 
control (tape test; 10 second contact time) 
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FIGURE 7: Release profiles of BD-loaded formulations on simulated lung fluid. 
 
FIGURE 8: Calu-3 cell viability as assessed by the trypan blue assay following incubation with 
polymer-lipid microparticles at specified concentrations in the range 0.1-2 mg/mL. (A) BD1 
microparticles, (B) BD2 microparticles, (C) BD3 microparticles, and (D) TEER values after cell 
exposure to 0.1 and 1 mg/mL at 4 h and at 8 h. 
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FIGURE 1  
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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FIGURE 6  
BD2 on double-sided 
tape, tested against the 
water control. 
BD2 on double-sided 
tape, tested against 
homogenized mucus. 
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FIGURE 7 
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FIGURE 8 
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